Post hoc 7-year analysis of the phase III CROWN trial in 296 untreated advanced ALK-positive NSCLC: median PFS not reached with lorlatinib vs 9.1 months with crizotinib (HR 0.19); 7-year PFS 55% vs 3%. Overall survival data immature.
Secondary analysisn = 296
Shaw et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study